Read by QxMD icon Read

Japanese Journal of Clinical Oncology

Y Sugawara, I Tsuji, T Mizoue, M Inoue, N Sawada, K Matsuo, H Ito, M Naito, C Nagata, Y Kitamura, A Sadakane, K Tanaka, A Tamakoshi, S Tsugane, T Shimazu
Background: There is a body of evidence to suggest that cigarette smoking increases the risk of cervical cancer in women, but no study has examined the magnitude of the association in Japanese women. Here, we evaluated the association between cigarette smoking and the risk of cervical cancer in Japanese women based on a systematic review of epidemiological evidence. Methods: Original data were obtained from a MEDLINE search using PubMed or from a search of the 'Ichushi' database, as well as by a manual search...
November 8, 2018: Japanese Journal of Clinical Oncology
Keiichi Ito, Ayako Masunaga, Nobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, Yota Yasumizu, Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, Shuji Mikami, Tetsuo Momma, Takeshi Masuda, Ken Nakagawa, Masafumi Oyama, Tomohiko Asano, Mototsugu Oya
Objectives: Progression-free survival of first-line targeted therapy greatly influences the survival of patients with metastatic renal cell carcinoma. We evaluated whether post-treatment inflammatory markers and lactate dehydrogenase levels had impacts on progression-free survival prediction in addition to those of conventional predictors. Methods: Two hundred and fifteen patients whose tumors were clear cell type and in whom first-line targeted therapies could be continued for >1 month were evaluated...
November 8, 2018: Japanese Journal of Clinical Oncology
Kozo Kataoka, Orit Kaider-Person, Bernd Kasper, Patrick Starlinger, Carmela Caballero, Jessica Menis, Lizza E Hendriks, Mitsumi Terada, Laurence Collette, Kenichi Nakamura, Denis Lacombe, Haruhiko Fukuda
International/intercontinental collaboration is necessary to set up new innovative clinical trials for cancer treatment. However, the infrastructure, especially Asia-Europe academic partnerships, to enable such collaboration has not been fully structured and differences and similarities between the research groups have not been well studied. In 2015, collaboration started between the biggest cancer research organizations in Asia and EU, Japan Clinical Oncology Group (JCOG) and European Organisation for Research and Treatment of Cancer (EORTC)...
November 5, 2018: Japanese Journal of Clinical Oncology
Yumi Wanifuchi-Endo, Tomoko Asano, Naoto Kondo, Yukari Hato, Yu Dong, Tomoka Hisada, Sayaka Nishikawa, Hiroyuki Kato, Satoru Takahashi, Katsuhiro Okuda, Hiroko Yamashita, Tatsuya Toyama
Background: Expression of estrogen receptor α in breast cancer is essential for estrogen-dependent growth and partially determines the breast cancer subtype. In premenopausal women, expression of estrogen-regulated genes in estrogen receptor-positive breast cancer tissues are reportedly influenced by the menstrual cycle. Methods: We investigated correlations between serum estradiol (E2; tested on the day of surgery) and expression of estrogen-regulated genes and proliferation genes in strongly estrogen receptor α-positive breast cancer tissues from 91 premenopausal women by quantitative reverse transcription-polymerase chain reaction...
November 5, 2018: Japanese Journal of Clinical Oncology
Eiko Saito, Megumi Hori
No abstract text is available yet for this article.
November 5, 2018: Japanese Journal of Clinical Oncology
Atsushi Yukimoto, Masashi Hirooka, Atsushi Hiraoka, Kojiro Michitaka, Hironori Ochi, Kouji Joko, Yusuke Imai, Takao Watanabe, Yohei Koizumi, Osamu Yoshida, Masanori Abe, Yoichi Hiasa
Background: Although sorafenib-regorafenib sequential therapy improves the prognosis of patients with hepatocellular carcinoma (HCC), many patients abandon sequential therapy due to worsening hepatic reserve function. Thus, it is important to clarify which patients can be treated using regorafenib. The albumin-bilirubin score is a good biomarker for hepatic reserve function. The aim of this study was to determine whether patient albumin-bilirubin scores at the start of sorafenib treatment could be used to identify candidates for subsequent regorafenib therapy...
October 31, 2018: Japanese Journal of Clinical Oncology
Takashi Matsuzuka, Naomi Kiyota, Junki Mizusawa, Tetsuo Akimoto, Masato Fujii, Yasuhisa Hasegawa, Shigemichi Iwae, Nobuya Monden, Kazuto Matsuura, Yusuke Onozawa, Ryuichi Hayashi, Makoto Tahara
Objectives: To evaluate the clinical impact of cachexia, defined by the combination of albumin and C-reactive protein levels, in patients with unresectable locally advanced head and neck squamous cell carcinomas who received chemoradiotherapy in a phase II trial of JCOG0706. Methods: Forty-five patients received radiation for a total of 70 Gy/35fr concurrently with S-1 and cisplatin. The present analysis was conducted in 44 patients with available data. The association between treatment efficacy and cachexia was investigated...
October 26, 2018: Japanese Journal of Clinical Oncology
Kiyo Tanaka, Nobuhiro Hanai, Junko Eba, Junki Mizusawa, Takahiro Asakage, Akihiro Homma, Naomi Kiyota, Haruhiko Fukuda, Ryuichi Hayashi
For stage I/II tongue cancer patients, it is controversial whether prophylactic neck dissection should be performed with partial glossectomy. Based on the evidence of the primary tumor's depth of invasion as a predictive factor of occult lymph node metastases and a prognostic factor of disease-free survival, randomized phase III trial was initiated in November 2017 to evaluate the omission value for prophylactic neck dissection for stage I/II tongue cancer with 3-10 mm of depth of invasion. In 5 years, 440 patients will be accrued from 28 institutions...
October 21, 2018: Japanese Journal of Clinical Oncology
Hidenori Suzuki, Kana Kimura, Takeshi Kodaira, Hiroyuki Tachibana, Natsuo Tomita, Yutaro Koide, Hiroshi Tanaka, Daisuke Nishikawa, Yusuke Koide, Shintaro Beppu, Nobuhiro Hanai
Objective: This study investigated whether gross tumor volume of the primary tumor before treatment was a predictor for local recurrence in patients with resectable sinonasal tract squamous cell carcinoma who were treated by chemoradiotherapy. Methods: A total of 24 patients were enrolled. Pretreatment gross tumor volume of primary tumor was assessed by palpitation, perception and imaging. The cut-off value of the gross tumor volume for local recurrence was determined by receiver-operating curve analysis...
October 20, 2018: Japanese Journal of Clinical Oncology
Megumi Ishiguro, Hideki Ueno, Yukihide Kanemitsu, Tetsuya Hamaguchi, Dai Shida, Yasuhiro Shimada
While the major Western guidelines recommend adjuvant chemotherapy for patients having Stage II colorectal cancer (CRC) with 'high-risk' features, e.g., pT4 and lymphovascular involvement, the survival benefit has not been confirmed. To understand the actual clinical practice for this patient subgroup in Japan, we performed a questionnaire survey of specialist institutions regarding two topics: institutional policy of adjuvant chemotherapy, and the percentage of patients receiving adjuvant chemotherapy among 'high-risk' Stage II CRC patients...
October 20, 2018: Japanese Journal of Clinical Oncology
Tomonori Mizutani, Kazuya Yamaguchi, Junki Mizusawa, Seiji Ito, Yasunori Nishida, Hiroshi Yabusaki, Narikazu Boku, Takeshi Sano, Kazuhiro Yoshida, Mitsuru Sasako, Takaki Yoshikawa, Masanori Terashima
Adjuvant chemotherapy with S-1 is a standard treatment for patients with stage II/III gastric cancer after D2 gastrectomy; however, this is not uniformly applicable in older patients. The Stomach Cancer Study Group of the Japan Clinical Oncology Group conducted a questionnaire survey on older patients aged ≥80 years and revealed wide heterogeneity among older patients of similar chronological age. This randomized trial aims to confirm the superiority of modified S-1 treatment (reduced initial dose of S-1 by ≥ 1 level compared with the standard dose) versus surgery alone in vulnerable older (≥80 years old) patients with pathological stage II/III gastric cancer after curative resection...
October 20, 2018: Japanese Journal of Clinical Oncology
Shinichi Togami, Toshihiko Kawamura, Mika Fukuda, Shintaro Yanazume, Masaki Kamio, Hiroaki Kobayashi
Background: The purpose of this study was to evaluate the occurrence of lymphatic complications following pelvic lymphadenectomy (PLA) in patients with cervical cancer. Methods: A retrospective study of 169 cervical cancer patients was conducted. Lower extremity lymphedema (LEL) was diagnosed using the International Society of Lymphology guidelines, and pelvic lymphocele (PL) was evaluated using trans-vaginal ultrasonography and computed tomography. Results: The median patient age was 46 years (range: 22-74) and median body mass index was 21...
October 17, 2018: Japanese Journal of Clinical Oncology
Risa Kanai, Kenta Tane, Genichiro Ishii, Jun Suzuki, Takashi Sakai, Satoshi Okada, Tomohiro Miyoshi, Keiju Aokage, Masahiro Tsuboi
Background: Gastric cancer metastasis to the lung can rarely manifest as solitary pulmonary nodule. The surgical strategies are different between metastasis from gastric cancer and primary lung cancer; therefore, the clinical prediction of solitary pulmonary nodule is important. Methods: Between September 2006 and September 2016, 38 patients with a history of curative resection for gastric cancer who subsequently underwent lung resection for solitary pulmonary nodule at our institution were evaluated...
October 15, 2018: Japanese Journal of Clinical Oncology
Mitsuya Ishikawa, Kenichi Nakamura, Taro Shibata, Kiyo Tanaka, Ryo Kitagawa, Hiroaki Kobayashi, Nobuo Yaegashi
A randomized controlled trial has been initiated to compare chemotherapy containing dose-dense paclitaxel plus carboplatin with or without bevacizumab to a conventional regimen containing tri-weekly paclitaxel plus carboplatin with or without bevacizumab. Eligible patients are those with stage IVB, recurrent or persistent cervical carcinoma not amenable to curative treatment with local therapy. Patients are randomly assigned to either the conventional or dose-dense regimen. However, patients who are at increased risk of adverse events following bevacizumab administration will not receive this drug...
October 8, 2018: Japanese Journal of Clinical Oncology
Aritoshi Hattori, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki
In the eighth edition of the TNM classification of lung cancer, the prognostic impact of tumor size is emphasized as a descriptor of all T categories. Especially in lung cancer where tumor size is 5 cm or less, the 1-cm cutoff point significantly differentiated the survival outcome. In addition, the new staging categories were assigned, namely, Tis (adenocarcinoma in situ) and T1mi (minimally invasive adenocarcinoma). Furthermore, the measurement of a radiological solid component size excluding the ground glass opacity component or pathological invasive size without a lepidic component was proposed for deciding the cT/pT categories for lung adenocarcinoma...
October 1, 2018: Japanese Journal of Clinical Oncology
Rikiya Onimaru, Hiroshi Onishi, Gakuto Ogawa, Masahiro Hiraoka, Satoshi Ishikura, Katsuyuki Karasawa, Yukinori Matsuo, Masaki Kokubo, Yoshiyuki Shioyama, Haruo Matsushita, Yoshinori Ito, Hiroki Shirato
Purpose: A dose escalation study to determine the recommended dose with stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinomas (JCOG0702) was conducted. The purpose of this paper is to report the survival and the late toxicities of JCOG0702. Materials and methods: The continual reassessment method was used to determine the dose level that patients should be assigned to and to estimate the maximum tolerated dose. The starting dose was 40 Gy in four fractions at D95 of PTV...
October 1, 2018: Japanese Journal of Clinical Oncology
Yongchun Liang, Mingming Zhou, Fanfan Wang, Zhishui Wu
Objectives: The objective of this meta-analysis is to systematically review the evidence on effects of exercise interventions in comparison to usual care with respect to physical fitness, fatigue, quality of life, anxiety and depression in hematopoietic stem cell transplantation patients for a hematological malignancies. And we are more focused on the optimal opportunity to exercise in hematopoietic stem cell transplantation recipients. Method: Databases were searched up to June 2018...
October 1, 2018: Japanese Journal of Clinical Oncology
Piao-Piao Jin, Shi-Yi Shao, Wang-Teng Wu, Xin-Yu Zhao, Bing-Feng Huang, Qi-Han Fu, Ri-Sheng Que, Qi-Da Hu
Background: The effectiveness of combination therapy of transarterial chemoembolization and sorafenib for unresectable hepatocellular carcinoma are controversial in some studies. This meta-analysis aims to compare efficacy and safety, as well as regional disparities, between transarterial chemoembolization plus sorafenib and transarterial chemotherapy alone for hepatocellular carcinoma. Methods: We systematically searched multiple databases to select eligible studies...
September 29, 2018: Japanese Journal of Clinical Oncology
Takashi Yamaguchi, Yoshinobu Matsuda, Hiromichi Matsuoka, Takayuki Hisanaga, Iwao Osaka, Hiroaki Watanabe, Isseki Maeda, Kengo Imai, Satoru Tsuneto, Yukiko Wagatsuma, Yoshiyuki Kizawa
Background: Guidelines recommend morphine as the first-line pharmacological treatment for cancer dyspnoea. However, trials with other opioids have not been performed. Our aim was to demonstrate the non-inferiority of oxycodone to morphine for relieving dyspnoea in cancer patients. Methods: We conducted a multicentre, open-label, parallel-group, randomized control trial. We randomly and equally assigned cancer patients on regular oxycodone who developed dyspnoea to get a single dose of oral immediate-release oxycodone or morphine...
September 27, 2018: Japanese Journal of Clinical Oncology
Jiqing Li, Xiao Li, Jianhua Gu, Xiaotian Ma, Fuzhong Xue
Background: Many patients with colorectal cancer are elderly with competing comorbidities. When constructing nomogram for assessing survival, we should consider the influence of competing risk. A competing-risks nomogram was developed to estimate the probability of death due to colorectal cancer for patients after curative surgery. Methods: A total of 2442 patients with non-metastatic colorectal cancer were included to develop competing-risks nomogram. Competing-risks nomogram were established based on the results of Fine and Gray competing-risks proportional hazards model...
September 25, 2018: Japanese Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"